Retrieve available abstracts of 6 articles: HTML format
Single Articles
May 2025
SARRAJU A, Brennan D, Hayden K, Stronczek A, et al Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction
(TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. 2025;405:1757-1768. PubMedAbstract available
December 2023
Familial hypercholesterolaemia in children and adolescents from 48 countries: a
cross-sectional study.
Lancet. 2023 Dec 12:S0140-6736(23)01842-1. doi: 10.1016/S0140-6736(23)01842. PubMedAbstract available
MCGOWAN MP, Cuchel M Universal paediatric screening for familial hypercholesterolaemia.
Lancet. 2023 Dec 12:S0140-6736(23)02182-7. doi: 10.1016/S0140-6736(23)02182. PubMed
November 2023
AYOUB A, Akyea RK, L'Esperance V, Ayis S, et al Determinants of lipid clinic referral and attendance in a multi-ethnic adult
population in south London: a cross-sectional study.
Lancet. 2023;402 Suppl 1:S26. PubMedAbstract available
September 2023
MANSFIELD BS, Raal FJ Regression of cutaneous xanthomata in patient with homozygous familial
hypercholesterolemia using novel therapies.
Lancet. 2023;402:e11. PubMed
March 2023
RIDKER PM, Bhatt DL, Pradhan AD, Glynn RJ, et al Inflammation and cholesterol as predictors of cardiovascular events among
patients receiving statin therapy: a collaborative analysis of three randomised
trials.
Lancet. 2023 Mar 3:S0140-6736(23)00215-5. doi: 10.1016/S0140-6736(23)00215. PubMedAbstract available